Business
Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness.Currently marketed contraceptives with similar results in their PCT clinical studies subsequently demonstrated 6-month “typical use” effectiveness of 86-91% in their pivotal clinical trials, in the same range as traditional hormonal contraceptive methods. SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from the Ovaprene postcoital test (PCT) clinical study, a multi-center, open-label, non-significant risk device pre-pivotal trial.\n Ovaprene is a novel hormone-free monthly vaginal contraceptive, designed to offer both once-a-month convenience and “typical use” effectiveness in the same range as traditional hormonal contraceptive methods (pills, patches, vaginal rings). While the use of oral contraceptive pills has declined in recent years, the utilization of non-oral forms of contraception, including contraceptive rings or patches, has increased.1 Worldwide sales of Merck’s monthly, hormonal vaginal ring NuvaRing® were over $900 million in 2018.2 The topline results from the PCT clinical study support continued clinical development of Ovaprene and its potential to be the first hormone-free, monthly contraceptive option for women. \"Market trends suggest there is a robust segment of women demanding alternatives to hormonal contraception and who prefer a once-a-month option,”3 said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “The PCT clinical study data, showing that Ovaprene prevented essentially all sperm from entering the cervical canal in 100% of women and 90% of women indicating they would recommend Ovaprene to a friend, are highly encouraging. These data give us confidence that Ovaprene has the potential to be an important new addition in the field of contraception and a much needed break-through product in the hormone-free category.” The PCT clinical study met its primary endpoint – Ovaprene prevented the requisite number of sperm from reaching the cervix across all women and all cycles evaluated. Specifically, in 100% of women and cycles, an average of less than five ( MeanMedianStandard DeviationInterquartileRangeBaseline PC...